Bladder Cancer Coverage from Every Angle

AUA 2021: Interim Analysis of Novel Immunotherapy for BCG-Unresponsive Bladder Cancer

By: Vanessa A. Carter, BS
Posted: Wednesday, September 22, 2021

Karim Chamie, MD, of UCLA Health Urology in Westwood, Los Angeles, and colleagues conducted the phase II/III QUILT 3.032 study on the addition of N-803—a mutant interleukin-15–based immunostimulatory fusion protein complex—to bacillus Calmette-Guérin (BCG) immunotherapy in patients with non–muscle-invasive bladder cancer. During the 2021 American Urological Association (AUA) Annual Meeting, the investigators revealed that N-803 yielded a complete response rate of 72%, meeting its primary endpoint with a 59% probability of complete responders maintaining complete response for at least 12 months (Abstract PD09-05).

“With the observed strong efficacy and a severe adverse event rate of 1%, N-803 represents a novel treatment option for BCG-unresponsive carcinoma in situ with a favorable benefit:risk ratio, in a therapeutically challenging disease,” the investigators concluded.

A total of 80 patients with high-risk non–muscle-invasive bladder cancer carcinoma in situ were enrolled into cohort A to receive N-803 plus BCG. Participants were previously unresponsive to BCG immunotherapy.

As mentioned, the complete response rate was 72%, with a median duration of complete response of 19.2 months. Low-grade treatment-related adverse events such as hematuria, pollakiuria, dysuria (16%), urgency (14%), and bladder spasm (8%) were among the most common; other adverse events affected less than 6% of individuals.

Treatment-emergent severe adverse events were observed in nine individuals, with a severe adverse event rate of 1% for any event. However, no treatment-emergent severe adverse events were considered to be related to treatment. Additionally, there appeared to be no immune-related severe events. A total of 10 participants proceeded to cystectomy.

Disclosure: No disclosure information was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.